Defining Hodgkin's Lymphoma

Hodgkin's lymphoma, a cancer of the immune system, is perhaps the most studied and researched cancer in human history. More time and energy and resources have gone into understanding Hodgkin's lymphoma than any other cancer. Why?

The short, simplistic answer probably has something to do with the fact that pioneering research scientists in the 1950s saw a glimmer of hope when they began testing different ideas on how to fight the cancer, and those early successes possibly fueled a greater interest in the disease. Instead of working on a solid tumor cancer and making no progress, those working on Hodgkin's were seeing real progress. In fact, the first combination chemotherapy regimen was developed for Hodgkin's lymphoma back around 1970.

Today Hodgkin's Lymphoma is treated with combination chemotherapy, involved-field radiation, antibody drug-conjugates, and occasionally, with bone marrow transplants.

It remains a very rare disease, with around 9,100 new cases diagnosed in the United States each year. The success of treatment has led to a cure rate for all stages of Hodgkin's lymphoma of approximately 75 to 80 percent. Early-stage cancers here have a 91 percent success rate.

Hodgkin's Defined

Hodgkin's is a cancer of the white blood cells (B-cells), but it is very different from non-Hodgkin's lymphomas, as well as other blood cancers like leukemia. Hodgkin's is defined by the presence of a specific kind of cell today known as the Reed-Sternberg cell.

Reed-Sternberg cells

Reed-Sternberg cells are abnormal cells that only appear in patients with Hodgkin's lymphoma. They are very large lymphocytes that often have more than one nucleus. In an overwhelming number of cases, Reed-Sternberg cells appear and signify Classical Hodgkin's lymphoma. In a very, very small subset of patients, Reed-Sternberg cells do not appear; instead large, abnormal Hodgkin's cells appear. This is known as lymphocyte-predominant Hodgkin's Lymphoma.

Disease Progression

Hodgkin's is also defined by the orderly progression of the disease. Unlike other lymphomas, which have no direction when they spread, and it is impossible to predict where the disease will go next, Hodgkin's is very reliable that way. It has a very orderly progression, one that physicians can count on and use to treat accordingly.

Symptoms

Finally, Hodgkin's can be loosely defined by its symptoms: Swollen and painless lymph nodes, unexplained fevers, night sweats, unexplained weight loss, itchy skin, and (sometimes) lymph node pain when consuming alcohol.

Despite all the advances against Hodgkin's and the high treatment success rate, at least 1,000 people in the US die each year from Hodgkin's, so it remains a potentially fatal disease.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap